

# GLOBAL DIFFERENCES AND SENTIMENTS ABOUT THE DRUG DEVELOPMENT INDUSTRY, ACCORDING TO DRUG DEVELOPERS

Uncovering the differences facing leading drug development companies based on insights from more than 150 biopharma and biotech leaders worldwide

## KEY TAKEAWAYS



APAC respondents were more likely to embrace innovation



European respondents relied more heavily on data science and analytics



US/Canadian respondents were slower to adapt to changes in the industry



## CHALLENGES

**Lack of specialized knowledge** presented more of a challenge for APAC respondents than any other region, with a quarter of APAC leaders surveyed reporting it as one of the top challenges facing their organization.

**26%** of APAC respondents

**9%** of European respondents

## OPPORTUNITIES + INNOVATION

### Data Science

Nearly half of European leaders surveyed viewed data science as an industry opportunity.

**44%** of European respondents

**19%** of APAC respondents

Two in three European drug developers currently use data science in their trials.

**65%** of European respondents

**45%** of US/Canada respondents

### Digitalization

European drug development leaders were more likely to use digitalization.

**74%** of European and APAC respondents

**46%** of US/Canada respondents

### AI

APAC and European drug developers were more optimistic about artificial intelligence.

**42%** of APAC respondents

**30%** of European respondents

**13%** of US/Canada respondents

### Wearables

APAC leaders were twice as likely to favor data collection through wearables/connected health devices.

**39%** of APAC respondents

**19%** of US/Canada respondents

### DCT

Two-thirds of APAC leaders reported that their organizations currently engage in decentralized, digital and remote trials.

**68%** of APAC respondents

**36%** of US/Canada respondents

## TIMELINE

European leaders surveyed were nearly three times more likely to perceive **no change in the speed of drug development over the past two years than other regions.**

**28%** of European respondents felt there has been no change in timeline

VS

**10%** of APAC respondents felt there has been no change in timeline

Half of respondents worldwide reported that that the **average timeline to produce a drug is longer** now than it was two years ago, compared to one-quarter reporting a faster timeline.

**48%** longer timeline

**24%** faster timeline

**20%** no change in timeline

**7%** unsure

The PPD clinical research business of Thermo Fisher Scientific is a leading global contract research organization focused on delivering life-changing therapies. Check out the rest of PPD's findings about the state of the drug development industry and learn how our experts can partner with you to simplify your next drug development project.